Management of Acromegaly With Pasireotide LAR: A Case Study of Sustained Biochemical Control and Tumor Volume Reduction Without Worsening of Glycemia
ABSTRACT: Objective: Pasireotide long-acting release (LAR), a next-generation, multireceptor-targeted somatostatin analogue with high binding affinity to somatostatin receptor type 5, has been shown to be superior to octreotide LAR in inducing biochemical control in a multicenter, phase III clinical...
Main Author: | Kevin C.J. Yuen, MD, FRCP (UK) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | AACE Clinical Case Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2376060520305927 |
Similar Items
-
Management of Hyperglycemia in a Patient with Acromegaly Treated with Pasireotide LAR: A Case Study
by: Murray B. Gordon, MD, FACE, et al.
Published: (2016-01-01) -
Pasireotide in the Personalized Treatment of Acromegaly
by: Manel Puig-Domingo, et al.
Published: (2021-03-01) -
Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
by: Hélène Lasolle, et al.
Published: (2019-10-01) -
Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia
by: Murray B Gordon, et al.
Published: (2017-05-01) -
Pasireotide: a novel treatment for patients with acromegaly
by: Cuevas-Ramos D, et al.
Published: (2016-01-01)